DMRA · Damora Therapeutics, Inc.
$29.99
-3.00 (-9.09%)
At close · Jul 22
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 12, 2026
Market Cap
$1.85B
Shares
61.55M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$209.84M
-878.8%
FY2025
Diluted EPS
$3.98
+121.5%
FY2025
Operating Cash Flow
-$6.73M
+63.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $4.16M | $1.17M | $844K | $1.69M | $722K | $156K | — | |
| $49.98M | $26.88M | $6.4M | $23.77M | $48.21M | $38.49M | $24.63M | |
| $14.8M | $9.69M | $10.5M | $12.69M | $13M | $13.74M | $9.01M | |
| — | $968K | $968K | $3.45M | — | — | — | |
| $239.08M | $210.87M | $22.26M | $39.91M | $61.21M | $52.23M | $33.64M | |
| -$239.08M | -$210.87M | -$22.26M | -$39.91M | -$61.21M | -$52.23M | $33.64M | |
| $4.09M | $1.08M | $862K | $1.56M | -$417K | $475K | -$1.2M | |
| -$235M | -$209.79M | -$21.4M | -$38.35M | -$61.62M | -$51.75M | -$34.84M | |
| $90K | $50K | $41K | $0 | $0 | $0 | $0 | |
| -$235.09M | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -$51.75M | -$34.84M | |
| — | — | — | — | — | — | -$34.84M | |
| -$234.64M | -$209.13M | -$21.72M | -$37.73M | -$61.55M | -$52.75M | -$31.71M | |
| USD/shares | — | $3.98 | -$18.53 | -$36.00 | -$60.75 | — | — |
| USD/shares | — | $3.98 | -$18.53 | -$36.00 | -$60.75 | — | — |
| shares | — | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 182.91K |
| shares | — | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 182.91K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.67×
P/E (TTM)
5.68×
Biotechnology median 7.06×